Centering discussion on the JAK inhibitor pacritinib, expert panelists review data from recent clinical trials and consider how they inform real-world use of this agent.
Expert panelists consider key molecular markers that guide the classification and management of myelofibrosis, along with other important subsets of disease.
/PRNewswire/ F Cancer, the 501(c)3 nonprofit, has launched their new website today with a fresh look, user-friendly interface, easy-to-navigate resources,.